P403 Post hoc examination of VISIBLE 1 data for baseline predictors of response to 2 or 3 IV doses of vedolizumab for adults with moderate-to-severe ulcerative colitis
ECCO'20 Vienna
2020
P404 Prolonged steroid exposure prior to admission is associated with increased likelihood of rescue therapy and colectomy in acute severe ulcerative colitis
ECCO'20 Vienna
2020
P405 Comparison of long-term outcomes of infliximab vs. adalimumab in 1488 biologic-naive Korean patients with Crohn’s disease
ECCO'20 Vienna
2020
P406 Adherence, acceptability and serum trough concentration of adalimumab autoinjector in quiescent patients with inflammatory bowel diseases
ECCO'20 Vienna
2020
P407 Is the rapid infliximab infusion a safe and cost-saving strategy in paediatric inflammatory bowel disease?
ECCO'20 Vienna
2020
P408 Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab
ECCO'20 Vienna
2020
P409 Endoscopic and histological activity is associated with non-response to biologic therapy in ulcerative colitis
ECCO'20 Vienna
2020
P410 Could the disease become ‘a friend’? The mediating role of illness acceptance on self-efficacy and quality of life of gastroenterological patients
ECCO'20 Vienna
2020
P412 Maintenance therapy of vedolizumab (VDZ) after induction of remission by tacrolimus (TAC) in patients with refractory ulcerative colitis (UC)
ECCO'20 Vienna
2020
P413 General impressions about nutrition in patients with inflammatory bowel disease using a nutritional survey
ECCO'20 Vienna
2020
P414 Risk factors for the development of anti-drug antibodies to infliximab and adalimumab in Crohn’s disease
ECCO'20 Vienna
2020
P416 Results of the first paediatric randomised controlled trial of faecal microbiota transplant for ulcerative colitis
ECCO'20 Vienna
2020
P417 Do ACE inhibitors and angiotensin II receptor blockers improve disease outcomes in inflammatory bowel disease?
ECCO'20 Vienna
2020
P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology
ECCO'20 Vienna
2020
P420 A randomised, observer-blinded phase Ib multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients
ECCO'20 Vienna
2020